Virtu Financial LLC Invests $40,000 in Theratechnologies Inc. (NASDAQ:THTX)

Virtu Financial LLC acquired a new stake in Theratechnologies Inc. (NASDAQ:THTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,902 shares of the company’s stock, valued at approximately $40,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Harbour Investments Inc. grew its holdings in Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after buying an additional 14,655 shares during the period. Raymond James Financial Inc. purchased a new stake in Theratechnologies in the fourth quarter valued at approximately $27,000. Wealthspire Advisors LLC grew its holdings in Theratechnologies by 39.0% in the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after purchasing an additional 20,000 shares during the period. Finally, National Bank of Canada FI increased its position in Theratechnologies by 29.4% during the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after purchasing an additional 42,435 shares during the last quarter.

Analysts Set New Price Targets

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Price Performance

Shares of NASDAQ THTX opened at $1.40 on Wednesday. The company has a market capitalization of $64.37 million, a price-to-earnings ratio of -14.00 and a beta of 1.24. Theratechnologies Inc. has a 1-year low of $1.08 and a 1-year high of $2.18. The business has a 50-day moving average of $1.63 and a 200-day moving average of $1.50.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.